

Mining Gene-Disease Associations with Open Targets

Webinar


Yale School of Medicine and friends

Denise Carvalho-Silva

Wellcome Genome Campus, United Kingdom
Open Targets Consortium
Core Bioinformatics team




Open Targets




The logistics for the next hour

- Presentation is uploaded in the ‘materials’ section as slides.pdf
- Exercises: anytime, at your own pace (coursebook.pdf)
Email support@targetvalidation.org for further discussions
- I’ll mute all microphones and take questions at the end
- Look out for the chat box



Chat box



Address chat to 'entire audience'.

Outline

- Drug Discovery and its the challenges
- The Open Targets Consortium
- The Open Targets Platform
- Quick live demo
- Get in touch

Webinar's objectives

What is the Open Targets Consortium?

What is the Open Targets Platform?


How to navigate the Platform?

How to connect with us




Open Targets

Drug discovery path: timeline




Drug discovery: the challenges




Lengthy, costly, low success rate, **HIGH ATTRITION RATES**

What are the causes for the attrition?

Pre-clinical




Phase I



Phase II



Phase III



- Pharmacokinetics/bioavailability
- Clinical safety
- Commercial
- Regulatory

- Non-clinical toxicology
- Efficacy
- Technical



*Professor Sir
Mike Stratton
Director, Sanger Institute*

Can we improve
target identification?



*Patrick Vallance, President
Pharmaceuticals R&D
GlaxoSmithKline*




*Professor Dame
Janet Thornton
former Director, EMBL-EBI*

Yes, we can!
And we should.

But one institution
can not do it alone.




Open Targets Consortium*



* Launched in March 2014
Three founding partners

Who is Open Targets?



*Biogen joined the consortium in February 2016


The two major areas of work* within Open Targets

Experimental projects



Generate new evidence
CRISPR
Organoids
Single cell RNASeq
Cell line fusion analyses
Metabolite GWAS

Core bioinformatics pipelines



Database for data integration
Web portal
REST API
Python client (fully supported)
R client (community)
Data dumps

* Concurrent
www.opentargets.org/projects


The two major areas of work* within Open Targets

Experimental projects



Generate new evidence
CRISPR
Organoids
Single cell RNASeq
Cell line fusion analyses
Metabolite GWAS

Core bioinformatics pipelines




Database for data integration
Web portal
REST API
Python client (fully supported)
R client (community)
Data dumps

Open Targets Platform*

- Developed by the Core Bioinformatics team at EMBL-EBI
- Allow scientists to identify target–disease associations
- Frequent updates: new data, new web features
- Improvements driven by our user communities


<https://www.targetvalidation.org/>



* First release: December 2015

Currently: Integration of existing data

Public Databases and Pipelines



Open Targets experimental data: NEW
Physiologically relevant and at scale

Oncology




Immunity



Cross-Disease



Neuro



Graphical user interface


Being generated
as we speak.



Open Targets

Evidence from publicly available data


- Similar data sources are grouped into data types



Data sources	Data types
GWAS catalog, UniProt, EVA, G2P	Genetic associations
Cancer Gene Census, EVA, IntOgen	Somatic mutations
Expression Atlas	RNA expression
ChEMBL	Drugs
Reactome	Affected pathways
Europe PMC	Text mining
PhenoDigm	Animal models
Your favourite data?	Let us know!

Confidence score for the T-D associations

Oliver Stegle's team (EMBL-EBI)



where is a harmonic series defined by
$$S_{1,i} = S_1 + \frac{S_2}{2^2} + \frac{S_3}{3^2} + \frac{S_4}{4^2} + \dots + \frac{S_i}{i^2}$$

It's allow for replication and deflates the effect of large amounts of data



Open Targets

We support decision-making

A) Which targets are associated with a disease?

B) What evidence supports this target-disease association?

F) What else can I find out about my drug target?

E) If this target is associated with other diseases, can I get the association for diseases from different therapeutic areas?

C) Are there FDA drugs for this association?

D) For a given target, are there other diseases associated with it?



Which targets are associated with a disease?



Demo 1:

screenshots: next slides
coursebook: pages 9 -15

The screenshot shows the Open Targets Platform website. A red arrow points from the question "Which targets are associated with a disease?" to the search bar. The search term "renal cell" is entered. Below the search bar, the results for "renal cell carcinoma" are displayed, showing 4543 targets associated with it. The results are categorized into Diseases and Targets. Under Diseases, it lists renal carcinoma and kidney disease. Under Targets, it lists PNN, GLIS2, and PRCC. The URL at the bottom of the slide is <https://www.targetvalidation.org/>.

renal cell

renal cell carcinoma
4543 targets associated

Disease

A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.. A carcinoma arising from the renal p...

Targets

PNN pinin, desmosome associated protein

GLIS2 GLIS family zinc finger 2

PRCC papillary renal cell carcinoma (translocation-associated)

Diseases

renal carcinoma

kidney disease > kidney neoplasm > renal carcinoma

papillary renal cell carcinoma

renal carcinoma > renal cell carcinoma > papillary renal cell carcinoma

<https://www.targetvalidation.org/>

15 targets associated with renal cell carcinoma

[View disease profile](#)

Filter the results

Filter by

Data types

[Clear all](#) [Select all](#)

- Genetic associations (15)
 - GWAS catalog (8)
 - UniProt literature (5)
 - European Variation Archive ... (4)
 - UniProt (3)
- Somatic mutations (526)
- Drugs (94)
- Affected pathways (0)
- RNA expression (3k)
- Text mining (2k)
- Animal models (1)

Pathway types

- [Clear](#)
- Developmental Biology
- Signal Transduction (3)
- Disease (2)
- Immune System (2)
- Cellular responses to stress (2)
- Chromatin organization (2)
- Metabolism (1)
- Cell Cycle (1)
- Metabolism of proteins (1)
- Circadian Clock (1)
- Vesicle-mediated transport (1)
- Gene Expression (1)

Target class

- Unclassified protein
- Enzyme (1)
- Epigenetic regulator (1)

Your target list

[Choose File](#) No file chosen

Target class
(Receptor, Kinase)

Showing 1 to 15 of 15 targets

Search:

Total number of targets associated with renal cell carcinoma based on Genetic association only

Data types
(Genetic Associations,
Drugs, etc)

Pathway types
(Metabolism,
Cell cycle)

Show 50 entries

No data

0  1

Score

Target symbol	Association score	Genetic associations	Somatic mutations	Drugs	Affected pathways	RNA expression	Text mining	Animal models	Target name
MET									MET proto-oncogene, receptor ...
VHL									von Hippel-Lindau tumor suppr...
PBRM1									polybromo 1
HNF1A									HNF1 homeobox A
SETD2									SET domain containing 2
FLCN									folliculin
EPAS1									endothelial PAS domain protein 1
MYC									v-myc avian myelocytomatosis ...
HNF1B									HNF1 homeobox B
MYEOV									myeloma overexpressed
ZEB2									zinc finger E-box binding home...
SCARB1									scavenger receptor class B me...
BHLHE41									basic helix-loop-helix family me...
PDZD2									PDZ domain containing 2
CEP85L									centrosomal protein 85 like

Previous 1 Next

[http://www.targetvalidation.org/
disease/EFO_0000681/associations?
fcts=datatype:genetic_association](http://www.targetvalidation.org/disease/EFO_0000681/associations?fcts=datatype:genetic_association)

Upload your own list



http://www.targetvalidation.org/disease/EFO_0000681

Open Targets Platform Survey About ▾ Help ▾ API ▾ Downloads

4543 targets associated with renal cell carcinoma


[View disease profile](#)

Phenotypes, Drugs, Disease Classification

“I’m really impressed with Open Targets. All this info in one place and for free?”



Drugs						
Source: CHEMBL						
Found 35 unique drugs: AFLIBERCEPT ALDESLEUKIN APITOLISIB AXITINIB AZD-2014 Anlotinib BEVACIZUMAB CABOZANTINIB EVEROLIMUS Farnitinib GIRENTUXIMAB INTERFERON ALFA-2A IXABEPILONE LINIFANIB MK-2206 NINTEDANIB NIVOLUMAB SEMAXANIB SORAFENIB SUNITINIB Savolitinib TANDUTINIB TEMSIROLIMUS TIVANTINIB TIVOZANIB VANDETANIB VOLOCXI						
Showing 1 to 10 of 1,000 entries						
Search:						
Drug Information						
Disease	Drug	Phase	Status	Type	Mechanism of action	Activity
renal cell carcinoma	EVEROLIMUS	Phase IV	Recruiting	Small molecule	FK506-binding protein 1A inhibitor DailyMed ↗	antagonist
renal cell carcinoma	EVEROLIMUS	Phase IV	Completed	Small molecule	FK506-binding protein 1A inhibitor DailyMed ↗	antagonist
renal cell carcinoma	EVEROLIMUS	Phase IV	Recruiting	Small molecule	FK506-binding protein 1A inhibitor DailyMed ↗	antagonist
clear cell renal carcinoma	AXITINIB	Phase IV	Recruiting	Small molecule	Vascular endothelial growth factor receptor inhibitor DailyMed ↗	antagonist



A possible use case



[Am J Hum Genet.](#) 2006 Jun; 78(6): 1011–1025.

Published online 2006 Apr 25. doi: [10.1086/504300](https://doi.org/10.1086/504300)

PMCID: PMC1474084

Reconstruction of a Functional Human Gene Network, with an Application for Prioritizing Positional Candidate Genes

[Lude Franke](#),¹ [Harm van Bakel](#),¹ [Like Fokkens](#),¹ [Edwin D. de Jong](#),² [Michael Egmont-Petersen](#),³ and [Cisca Wijmenga](#)¹

- Detect disease genes from a functional gene network
- 96 diseases (Mendelian and complex inheritance, cancer)
- 345 unique disease genes
- e.g. renal cell carcinoma (papillary) and *MET*

Demo 2: Evidence supporting the *MET*-papillary renal cell carcinoma association

- Which genetic evidence supports this association?
- Can you view this in a genome browser display?
- Are there any drugs in clinical trials for this disease?
- Is there a mouse model that mimics this disease?
- Which tissue has the highest RNA expression from GTEx?
- Are there other kidney diseases associated with this target? Can you export the table with this information? How strong is this association?

Choose your favourite internet browser*

*Supported ones: Internet Explorer 11 (and above), Chrome, Firefox and Safari

Demo 3: your list of targets for a disease

Franke et al (2006) described seven genes associated with Alzheimer's disease: ENSG00000091513, ENSG00000175899, ENSG00000143801, ENSG00000142192, ENSG00000130203, ENSG00000010704, ENSG00000080815.

- Which of these have the strongest association w/ Alzheimer's?
- Are there any targets, which are membrane receptors?
- Which amino acids of this membrane receptor (putative drug target) correspond to the extracellular domain?

Exercises

Pages 24-27, 33-35

*Learn at a pace that works for you.
You can get in touch at any time!*



support@targetvalidation.org

Wrap up

Open Targets Platform is the place:

For drug target ID and selection in drug discovery

Rank target-disease associations: different sources

Integrated information on target and diseases

Intuitive graphical user interface

Oh Yes!
And all is 100% free
and open source



Open Targets

Alternative ways to access the data

Looking for our entire datasets?

<https://www.targetvalidation.org/downloads/data>

- All target-disease associations: 215 MB
- All evidence: 4.35 GB

Looking for extracts of our datasets?

- API: REST calls, Python client
- R client: maintained by the community



Open Targets

How to cite us

Published online 8 December 2016

Nucleic Acids Research, 2017, Vol. 45, Database issue D985–D994
doi: 10.1093/nar/gkw1055



Open Targets: a platform for therapeutic target identification and validation

Gautier Koscielny^{1,2,*}, Peter An^{1,3}, Denise Carvalho-Silva^{1,4}, Jennifer A. Cham^{1,4}, Luca Fumis^{1,4}, Rippa Gasparyan^{1,3}, Samiul Hasan^{1,2}, Nikiforos Karamanis^{1,4}, Michael Maguire^{1,4}, Eliseo Papa^{1,3}, Andrea Pierleoni^{1,4}, Miguel Pignatelli^{1,4}, Theo Platt^{1,3}, Francis Rowland^{1,4}, Priyanka Wankar^{1,3}, A. Patrícia Bento^{1,4}, Tony Burdett^{1,4}, Antonio Fabregat^{1,4}, Simon Forbes^{1,5}, Anna Gaulton^{1,4}, Cristina Yenyxe Gonzalez^{1,4}, Henning Hermjakob^{1,4,6}, Anne Hersey^{1,4}, Steven Jupe^{1,4}, Şenay Kafkas^{1,4}, Maria Keays^{1,4}, Catherine Leroy^{1,4}, Francisco-Javier Lopez^{1,4}, Maria Paula Magarinos^{1,4}, James Malone^{1,4}, Johanna McEntyre^{1,4}, Alfonso Munoz-Pomer Fuentes^{1,4}, Claire O'Donovan^{1,4}, Irene Papatheodorou^{1,4}, Helen Parkinson^{1,4}, Barbara Palka^{1,4}, Justin Paschall^{1,4}, Robert Petryszak^{1,4}, Naruemon Pratanwanich^{1,4}, Sirarat Sarntivijal^{1,4}, Gary Saunders^{1,4}, Konstantinos Sidiropoulos^{1,4}, Thomas Smith^{1,4}, Zbyslaw Sondka^{1,5}, Oliver Stegle^{1,4}, Y. Amy Tang^{1,4}, Edward Turner^{1,4}, Brendan Vaughan^{1,4}, Olga Vrousou^{1,4}, Xavier Watkins^{1,4}, Maria-Jesus Martin^{1,4}, Philippe Sanseau^{1,2}, Jessica Vamathevan⁴, Ewan Birney^{1,4}, Jeffrey Barrett^{1,4,5} and Ian Dunham^{1,4,*}

¹Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK, ²GSK, Medicines Research Center, Gunnels Wood Road, Stevenage, SG1 2NY, UK, ³Biogen, Cambridge, MA 02142, USA, ⁴European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK, ⁵Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK and ⁶National Center for Protein Research, No. 38, Life Science Park Road, Changping District, 102206 Beijing, China

Received August 19, 2016; Revised October 19, 2016; Editorial Decision October 20, 2016; Accepted November 03, 2016

Acknowledgements



support@targetvalidation.org



Open Targets

Get in touch



@targetvalidate



support@targetvalidation.org



www.facebook.com/OpenTargets/



blog.opentargets.org/



<http://tinyurl.com/opentargets-in>


Extra slides

How do we associate diseases and phenotypes w/ targets?

- 1 ChEMBL, UniProt, EVA (w/ ClinVar) curate diseases and phenotypes
- 2 Map disease/phenotypes to an ontology using EFO and HPO terms
- 3 Use genes as proxies for our targets
- 4 Create target-disease evidence JSON objects
- 5 Calculate for each supporting evidence the likelihood of gene A being associated with disease B
- 6 Compute integrated target-disease scores at the levels of data source, data type and overall score

Experimental Factor Ontology* (EFO)

- Ontology: smart dictionary → relationships between entities
- EFO: way to organise experimental variables (e.g. diseases)



controlled vocabulary
+
hierarchy (relationship)

* <https://www.ebi.ac.uk/efo/>

Increases the richness of annotation
Promotes consistency
Allow for easier and automatic integration

How confident can you be of the target-disease associations in Open Targets?

Statistical integration, aggregation and scoring*

- A) per evidence (e.g. lead SNP from a GWAS paper)
- B) per data source (e.g. GWAS catalog)
- C) per data type (e.g. Genetic associations)
- D) overall

*https://github.com/opentargets/association_score_methods

Factors affecting the relative strength of an evidence


e.g. *GWAS Catalog*

$$S = f * s * c$$

f, relative occurrence of a target-disease evidence

s, strength of the effect described by the evidence

c, confidence of the observation for the target-disease evidence



f= sample size (cases versus controls)

s = predicted functional consequence

c = *p*-value reported in the paper

Aggregating scores across the data

- Using a mathematical function, the harmonic sum*

$$S_{1..i} = S_1 + \frac{S_2}{2^2} + \frac{S_3}{3^2} + \frac{S_4}{4^2} \dots + \frac{S_i}{i^2}$$

where S_1, S_2, \dots, S_i are the individual sorted evidence scores in descending order

- Advantages:
 - A) account for replication
 - B) deflate the effect of large amounts of data e.g. text mining

* PMID: 19107201, PMID: 20118918


Disclaimer: score, dos and don'ts

- It's a ranking of target-disease associations
- It shows how confident we are in the association
- It's based on data sources, publicly available



- It can help you to design your null hypothesis
- It can help you to decide which target to pursue
- It is NOT sufficient on its own (use it in combination with...)

Ranking the target-disease association



- Based on the data sources
- Different weight applied:

genetic association = drugs = mutations = pathways > RNA expression > animal models = text mining

REST API endpoints



public : Publicly supported stable API.

Open/Hide | List operations | Expand operations

GET /public/evidence

POST /public/evidence

GET /public/evidence/filter

POST /public/evidence/filter

GET /public/association

GET /public/association/filter

POST /public/association/filter

GET /public/search

GET /public/auth/request_token

GET /public/auth/validate_token

GET /public/utils/ping

GET /public/utils/version

GET /public/utils/stats

- Query association and evidence by gene identifiers and diseases
- Filter by type of evidence

<https://www.targetvalidation.org/documentation/api>

GET

/public/association



Implementation notes

After integrating all evidence connecting a target to a specific disease, we compute an association score by mean of an harmonic sum. This association score provides an indication of how strong the evidence behind each connection is and can be used to rank genes in order of likelihood as drug targets. The association id is constructed by using the ensembl id of the gene and the EFO id for the disease (eg. ENSG00000073756-EFO_0003767). The method returns an association object, which contain data and summary on each evidence type included in the calculation of the score, as well as the score itself.

Parameters

Parameter	Value	Description	Parameter type	Data type
id	ENSG00000073756-EFO_0003767	an association ID usually in the form of TARGET_ID-DISEASE_ID	query	string

Response messages

HTTP status code	Reason	Model
200	Successful response	

[Try it out!](#)[Hide response](#)

Request URL

https://www.targetvalidation.org/api/latest/public/association?id=ENSG00000073756-EFO_0003767



Response body

```
{  
  "from": 0,  
  "facets": null,  
  "took": 6,  
  "therapeutic_areas": [],  
  "total": 1,  
  "data": [  
    {  
      "target": {  
        "gene_info": {  
          "symbol": "PTGS2",  
          "ensembl_id": "ENSG00000073756",  
          "name": "PTGS2",  
          "chromosome": 12, "start": 123456789, "end": 123456789},  
        "evidence": [{"source": "Ensembl", "score": 100, "type": "Gene-Disease"}, {"source": "OMIM", "score": 80, "type": "Gene-Disease"}],  
        "summary": "PTGS2 is associated with various diseases, including PTGS2-related disorders."},  
      "disease": {  
        "name": "PTGS2-associated disorder",  
        "efo_id": "EFO_0003767",  
        "description": "A rare genetic disorder caused by mutations in the PTGS2 gene, leading to developmental delay and other symptoms."},  
        "score": 100, "harmonic_mean": 100, "count": 2},  
      "method": "Harmonic Mean",  
      "date": "2023-10-01",  
      "version": "v1.0"}]
```

- Paste the URL in a location bar in a browser
- Use the terminal window (e.g. with CURL)
- Use one of our clients (i.e. R and Python)

Python and R clients for the REST API

opentargets
latest

Search docs

Tutorial
High Level API
Low Level API
Code Documentation
Changelog


Docs » opentargets - Python client for targetvalidation.org

Edit on GitHub

opentargets - Python client for targetvalidation.org

opentargets is the official python client for the [Open Targets REST API](#) at [targetvalidation.org](#)

<http://opentargets.readthedocs.io>



[https://blog.opentargets.org/
rest-api-exploration-using-
an-r-client/](https://blog.opentargets.org/rest-api-exploration-using-an-r-client/)

How to access Open Targets
with R